Within the United States tax code, domestic and foreign research‑and‑development (R&D) expenditures are treated very differently. Domestic R&D can be deducted immediately under Section 174A—or amortized over a minimum of 60 months—while foreign R&D must be capitalized and amortized over 15 years under Section 174, with no option for immediate expensing. This disparity creates hidden costs for U.S. multinationals that conduct R&D abroad.
Domestic vs. foreign R&D treatment
- Section 174A (domestic R&D) – Taxpayers may either:
- Deduct the full cost in the year incurred (full expensing), or
- Amortize the expense over at least 60 months if they cannot use the full deduction immediately (e.g., because of a net operating loss).
- Section 174 (foreign R&D) – Must be capitalized and amortized uniformly over 15 years; immediate expensing is not permitted.
The divergence stems from the “One Big Beautiful Bill Act” (OBBBA), which restored full expensing for domestic R&D but left foreign R&D unchanged, likely to reduce the budgetary impact of the reform and to encourage onshoring of R&D activities.
How timing affects marginal R&D investment
The Hall‑Jorgenson framework (1967) shows that the timing of tax deductions influences the user cost of capital, c, the hurdle rate a project must exceed to be undertaken. A key variable, z, represents the present value of tax deductions relative to the tax rate, τ. When z = 1 (full expensing), the tax component of c cancels, making the marginal tax burden effectively zero. Conversely, amortizing deductions over 15 years reduces z below 1, raising c and discouraging marginal projects.
- Full expensing → Immediate tax benefit; marginal projects face no additional tax cost.
- Amortization (foreign R&D) → Deductions spread over 15 years; marginal projects incur a higher effective tax rate, reducing the incentive to invest at the margin.
While inframarginal projects (those with clear net benefits) still generate taxable income, the higher user cost for marginal R&D can lead to the abandonment of otherwise viable innovations.
Foreign R&D is complementary, not substitutive
Economic research indicates that foreign R&D typically augments domestic innovation rather than replacing it. Examples include:
- Market adaptation – Adjusting U.S.-developed products for foreign languages, climates, infrastructure, or regulatory regimes to enable export.
- Acquisition of foreign research teams – Integrating overseas talent and patents into U.S. operations, often prompting further domestic investment.
Studies by Gary Hufbauer, Theodore Moran, and Lindsay Oldenski, as well as analyses from the Information Technology and Innovation Foundation, find that global R&D activities of U.S. multinationals create complementary capabilities and interdependent competencies. Penalizing foreign R&D would likely diminish total cross‑border knowledge production without delivering domestic gains.
Impact on cross‑border mergers and acquisitions
When foreign R&D must be amortized over 15 years for a U.S. acquirer, the after‑tax valuation of an R&D‑intensive target is lower than for a foreign competitor that can expense the same R&D immediately. This valuation gap can:
- Reduce the competitiveness of U.S. firms in M&A bidding wars, particularly in sectors such as semiconductors and pharmaceuticals.
- Lead to fewer successful acquisitions, limiting the global reach and revenue generation of U.S. multinationals and, by extension, the U.S. tax base.
Policy implication
A neutral tax treatment of R&D—regardless of where the activity occurs—would eliminate the hidden cost of foreign R&D amortization, encourage broader innovation, and preserve the ability of U.S. firms to compete for foreign assets. Aligning the tax code for domestic and foreign R&D could sustain the complementary benefits of global research while avoiding distortions that discourage marginal investment and cross‑border M&A activity.
Source article: taxfoundation.org
